Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2000
10/12/2000WO2000059887A1 Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics
10/12/2000WO2000059886A2 Benzimidazole abd imidazolophyridine derivaties, their preparation and their use as selective modulators of bradykinin b2 (=bk-2) receptors
10/12/2000WO2000059884A1 Pharmaceutically active compounds and methods of use thereof
10/12/2000WO2000059882A1 Anticancer calcium channel blockers
10/12/2000WO2000059881A1 Substituted azetidin-2-ones as cysteine protease inhibitors
10/12/2000WO2000059878A2 INHIBITORS OF LFA-1 BINDING TO ICAMs AND USES THEREOF
10/12/2000WO2000059875A2 Novel inhibitors of formation of advanced glycation endproducts (age's)
10/12/2000WO2000059874A1 NOVEL AMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES, TNF-α, AND AGGRECANASE
10/12/2000WO2000059873A1 N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists
10/12/2000WO2000059866A1 Compounds derived from benzoic acid esters, composition containing said compounds and use thereof
10/12/2000WO2000059864A1 Lta4 hydrolase inhibitors
10/12/2000WO2000059855A1 Ether compounds, compositions, and uses thereof
10/12/2000WO2000059851A1 Derivatives of venlafaxine and methods of preparing and using the same
10/12/2000WO2000059577A1 Low dose estrogen interrupted hormone replacement therapy
10/12/2000WO2000059548A1 Polyethyleneimine:dna formulations for aerosol delivery
10/12/2000WO2000059546A2 Methods and compositions for drug delivery
10/12/2000WO2000059545A1 Modification of sexual behaviour in animals and pest control
10/12/2000WO2000059544A1 Stabilized compositions containing nootropic drugs
10/12/2000WO2000059542A1 Method for a programmed controlled ovarian stimulation protocol
10/12/2000WO2000059541A1 Preventives or remedies for cancer and method for screening the same
10/12/2000WO2000059525A2 USE OF ErbB RECEPTOR LIGANDS IN TREATING DIABETES
10/12/2000WO2000059522A1 Compositions and methods for treatment of diabetes
10/12/2000WO2000059518A2 Composition and method for inducing apoptosis in prostate cancer cells
10/12/2000WO2000059517A1 Ceramide and chemotherapeutic agents for inducing cell death
10/12/2000WO2000059515A2 Immunomodulating polymers
10/12/2000WO2000059513A1 NON-CALCEMIC, ANTIPROLIFERATIVE, TRANSCRIPTIONALLY ACTIVE SULFUR-CONTAINING ANALOGS OF 1α, 25-DIHYDROXY VITAMIN D¿3?
10/12/2000WO2000059512A1 Formulation comprising testosteron undecanoate and castor oil
10/12/2000WO2000059511A1 Use of tianeptin in the production of medicaments to treat neurodegenerative pathologies
10/12/2000WO2000059510A1 Aminopyrimidines as sorbitol dehydrogenase inhibitors
10/12/2000WO2000059509A1 Phthalazine derivatives for treating inflammatory diseases
10/12/2000WO2000059508A1 Tolperison-containing, pharmaceutical preparation for oral administration
10/12/2000WO2000059507A1 Obesity preventives
10/12/2000WO2000059506A1 HETEROCYCLIC CONTAINING BIPHENYL aP2 INHIBITORS AND METHOD
10/12/2000WO2000059505A1 Inhibitors for vascular reconstriction after angioplasty
10/12/2000WO2000059504A1 Method for the treatment of neurological or neuropsychiatric disorders
10/12/2000WO2000059503A1 Pyrrolidine modulators of chemokine receptor activity
10/12/2000WO2000059502A1 Pyrrolidine modulators of chemokine receptor activity
10/12/2000WO2000059501A1 Water-soluble trioxanes as potent and safe antimalarial agents
10/12/2000WO2000059500A1 Swallowable tablets with high content of n-acetylcysteine
10/12/2000WO2000059499A1 Use of succinic acid or salts thereof for the treatment of diabetes mellitus and wound healing
10/12/2000WO2000059496A1 Use of low affinity nmda antagonists for the treatment of headache
10/12/2000WO2000059495A1 (e)-styryl sulfone anticancer agents
10/12/2000WO2000059494A1 Styryl sulfone anticancer agents
10/12/2000WO2000059493A2 Improved dialysis solutions and methods
10/12/2000WO2000059492A2 Anti-tumor activity of vitamin e, cholesterol, taxol and betulinic acid derivatives
10/12/2000WO2000059491A2 Methods for modulating the human sexual response
10/12/2000WO2000059490A2 Immunomodulating composition for use especially in the treatment of inflammations, infections and surgical adhesions
10/12/2000WO2000059489A2 Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites
10/12/2000WO2000059488A2 Enhanced tissue and subcellular delivery of vitamin e compounds
10/12/2000WO2000059487A2 Flupirtine in the treatment of fibromyalgia and related conditions
10/12/2000WO2000059486A2 Use of cyp2d6 inhibitors in combination therapies
10/12/2000WO2000059485A2 Pharmaceutical compositions comprising in combination a bisphosphonate and a matrix metalloproteinase inhibitor
10/12/2000WO2000059484A2 Use of arylalkanoylpyridazines
10/12/2000WO2000059483A2 Transdermal drug delivery devices comprising a polyurethane drug reservoir
10/12/2000WO2000059482A1 Oral pharmaceutical compositions containing long-chain triglycerides and lipophilic surfactants
10/12/2000WO2000059481A1 PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF d-threo-METHYLPHENIDATE AND A SECOND CNS STIMULANT
10/12/2000WO2000059479A1 Pharmaceutical dosage form for pulsatile delivery of methylphenidate
10/12/2000WO2000059477A1 Pregelatinized starch in a controlled release formulation
10/12/2000WO2000059476A1 Methods for fine powder formation
10/12/2000WO2000059473A1 Compositions and methods for treating lymphoma
10/12/2000WO2000059472A1 Propofol compositions containing preservative additives
10/12/2000WO2000059471A1 Propofol formulation with enhanced microbial characteristics
10/12/2000WO2000059469A2 Endodontic fibers and methods of use therefor
10/12/2000WO2000059468A1 Drinkable pharmaceutical solution
10/12/2000WO2000059467A1 Drinkable ibuprofen pharmaceutical suspension
10/12/2000WO2000059449A2 Purine derivatives having phosphodiesterase iv inhibition activity
10/12/2000WO2000059448A2 Association of no-synthase inhibitor(s) and metabolic antioxidant(s)
10/12/2000WO2000059447A2 Use of sex hormones to obtain a nasal pharmaceutical composition that is useful in the treatment of undesirable uterine bleeding
10/12/2000WO2000059304A1 Compositions and methods for preventing and treating sexual dysfunctions
10/12/2000WO2000059303A1 Oxidized polyunsaturated fatty acids having anti-proliferative activity and methods of use
10/12/2000WO2000038747A3 Absorbent article composition and method of use for sequestering skin irritants
10/12/2000WO2000037037A3 Composition for treatment of burns
10/12/2000WO2000035939A3 Connective tissue growth factor fragments and methods and uses thereof
10/12/2000WO2000035422A3 Method of administering a compound to multi-drug resistant cells
10/12/2000WO2000033874A3 Boron neutron capture therapy using pre-targeting methods
10/12/2000WO2000033820A3 Nanoparticulate core-shell systems and use thereof in pharmaceutical and cosmetic preparations
10/12/2000WO2000033811A3 Improvements in or relating to powders
10/12/2000WO2000032803A3 Novel nucleic acid transferring agents, compositions containing them and uses
10/12/2000WO2000027196B1 Use of gm-csf to inhibit development of drug resistance in hiv+ patients
10/12/2000WO2000021513A9 Methods for treating multiple sclerosis
10/12/2000WO2000020587A3 Cancer associated antigens and uses therefor
10/12/2000WO2000018918A9 Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity
10/12/2000WO2000017232A3 Regulatory protein from human keratinocytes
10/12/2000WO2000015790A9 Leptin induced genes
10/12/2000WO2000009106A3 Carboxylic acids and isosteres of heterocyclic ring compounds having multiple heteroatoms for vision and memory disorders
10/12/2000WO2000002549A3 Composition for and method of treating neurological disorders
10/12/2000WO1999064594A9 Genes and gene expression products that are differentially regulated in prostate cancer
10/12/2000WO1999064039A9 Bradykinin antagonists
10/12/2000WO1999038841A8 Adamantanecarboximidamide derivatives and their use as nmda antagonists
10/12/2000WO1998025597A3 Method for treating and preventing heart failure and ventricular dilatation
10/12/2000WO1993012754A3 Tertiary and secondary amines as alpha-2 antagonists and serotonin uptake inhibitors
10/12/2000DE19915365A1 Tetrahydropyridazin-Derivate Tetrahydropyridazine derivatives
10/12/2000DE19915364A1 Verwendung von Arylalkanoylpyridazinen Use of Arylalkanoylpyridazinen
10/12/2000DE19829448A1 1-Octadecyl-2-methyl-sn-glycero-3-phosphocholin (ET180CH3) zur Behandlung von humanen Mammakarzinomen 1-octadecyl-2-methyl-sn-glycero-3-phosphocholine (ET180CH3) for the treatment of human breast carcinomas
10/12/2000DE10004815A1 Human sodium-phosphate cotransporter Npt2B, useful e.g. for identifying agents for treating hyper- and hypo-phosphatemia, and related nucleic acid
10/12/2000CA2373717A1 Pyrrolidine modulators of chemokine receptor activity
10/12/2000CA2369871A1 .alpha.-substituted carboxylic acid derivatives
10/12/2000CA2369557A1 Aryl and heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of gabaa receptors
10/12/2000CA2369553A1 N-benzimidazolylmethyl and n-indolylmethyl-benzamides and their use as crf modulators
10/12/2000CA2369549A1 Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics
1 ... 6229 6230 6231 6232 6233 6234 6235 6236 6237 6238 6239 6240 6241 6242 6243 6244 6245 6246 6247 6248 6249 ... 7860